Skip to content

Diagnostic ultrasound stimulated microbubbles combined with vasodilators enhance blood perfusion in solid tumors with poor blood supply: a multicenter self controlled study

Diagnostic ultrasound stimulated microbubbles combined with vasodilators enhance blood perfusion in solid tumors with poor blood supply: a multicenter self controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126704
Enrollment
Unknown
Registered
2026-06-14
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer or breast cancer with lack of blood supply

Interventions

Experimental group:Ultrasound stimulated microbubbles combined with vasodilator

Sponsors

The Second Affiliated Hospital of the PLA Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The patient is required to sign the informed consent form; 2. Patients diagnosed with pancreatic cancer and breast cancer through pathological histology or cytology and requiring chemotherapy; 3. Patients with measurable and evaluable tumor lesions as determined by oncological assessment (ultrasound, CT or MRI), and diagnosed with pancreatic cancer and breast cancer with poor blood supply (in this study, we define poor blood supply as the blood perfusion area in the largest tumor section on ultrasound contrast imaging being less than 40% of the total tumor area); 4. Age 18-75 years old, gender not limited; 5. Expected survival period of more than 3 months; 6. WBC >= 3.5×10^9/L, ANC >= 1.5×10^9/L, PLT >= 80×10^9/L, Hb >= 90/L; 7. Laboratory test results confirm good function of all organs, ECOG score 0-1; 8. No history of other malignant tumors; 9. Good compliance, no mental disorders.

Exclusion criteria

Exclusion criteria: 1. Does not meet the inclusion criteria; 2. Pregnant or breastfeeding; 3. Allergic or hypersensitive to chemotherapy drugs and vasodilators; 4. Intestinal obstruction or incomplete intestinal obstruction; 5. Acute active infectious diseases, autoimmune diseases or immunodeficiency diseases history; 6. Large ascites; 7. With brain or bone metastases; 8. Undergoing other anti-tumor drug treatment or radiotherapy; 9. Participating in other clinical trials with an end time less than 4 weeks; 10. Acute myocardial infarction and low filling pressure; 11. Left heart dysfunction and low filling pressure; 12. Severe hypotension (systolic blood pressure lower than 90 mmHg); 13. Hypertrophic obstructive cardiomyopathy; 14. Constrictive pericarditis; 15. Pericardial tamponade; 16. Glaucoma; 17. Aortic stenosis or mitral stenosis; 18. Patients with severe liver and kidney function impairment; 19. Hypothyroidism, malnutrition and patients with low body weight.

Design outcomes

Primary

MeasureTime frame
Area under curve difference;

Secondary

MeasureTime frame
Peak intensity;

Countries

China

Contacts

Public ContactXiaoxiao Dong

The Second Affiliated Hospital of Army Medical University

dongxiaoxiao@tmmu.edu.cn+86 23 6877 4698

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 29, 2026